Understand the source comparison
LIPO-C Blood Work Labs: Before vs After Comparison
ALT (Alanine Aminotransferase) 10–40 IU/L +10 to +20 IU/L Transient elevation reflects increased hepatocyte membrane turnover during fat mobilization—expected with methyl donor therapy Normal if GGT remains stable; concerning if GGT rises proportionally AST (A
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ALT (Alanine Aminotransferase)
- 10–40 IU/L
- +10 to +20 IU/L
- Transient elevation reflects increased hepatocyte membrane turnover during fat mobilization—expected with methyl donor therapy
- Normal if GGT remains stable; concerning if GGT rises proportionally
- AST (Aspartate Aminotransferase)
- 10–34 IU/L
- +5 to +15 IU/L
- Less specific than ALT (also found in muscle, heart)—mild elevation expected during active lipotropic metabolism
- Acceptable if AST:ALT ratio stays below 1.5 and CK is normal
- GGT (Gamma-Glutamyl Transferase)
- 9–48 IU/L
- Stable or −5 to −10 IU/L
- Differentiates productive fat metabolism from liver inflammation—should NOT rise during therapeutic lipotropic use
- Rising GGT alongside ALT/AST signals liver stress, not therapeutic effect
- Triglycerides
- 50–150 mg/dL
- −15% to −25% reduction
- Direct measure of VLDL export efficiency—if this doesn't drop, methyl donors aren't reaching lipid packaging pathways
- Primary endpoint—lack of reduction suggests protocol inefficacy or dietary interference
- LDL Cholesterol
- 70–130 mg/dL
- −8% to −12% reduction
- Secondary lipid marker—improves as hepatic lipid processing normalizes
- Meaningful only if triglycerides also drop; isolated LDL change is not lipotropic-specific
- HDL Cholesterol
- 40–60 mg/dL
- Stable or +3 to +8 mg/dL
- Protective cholesterol—slight increase indicates improved reverse cholesterol transport
- Rising HDL + falling triglycerides = strong metabolic response